ONLINE SUBMISSION
  April, 2010

Ewing’s Sarcoma/PNET of kidney in 13 year old girl

  Quratulain Badar, Nadeem Abbasi, Farrok Karsan  ( Department of Radiation Oncology the Aga Khan University Hospital, Karachi, Pakistan. )
Nasir Ali, Raheel Hashmi  ( Department of Radiation Oncology, The Aga Khan University Hospital, Karachi. )
Shamvil Ashraf  ( Children Cancer Hospital, Karachi, Pakistan )
 

Abstract

Ewing's sarcoma is the second most common primary tumour of bone in childhood. Less frequently it occurs in soft tissues. Ewing's sarcoma/primitive neuroectodermal tumour (ES/PNET) is an extra ordinarily rare primary tumour in the kidney.1 Only very few cases of primary renal Ewing's sarcoma have been reported in the literature to date.2 We present a case of primary right renal Ewing's sarcoma in a 13 year old girl who was diagnosed as a case of stage IV ES/PNET of kidney with metastases to lung and liver. Right nephrectomy was done followed by adjuvant radiotherapy and chemotherapy with complete response to local and distant area.


Introduction

Ewing's sarcoma is the second most common tumour of bone in childhood. Less frequently it occurs in soft tissues. In the European Intergroup Cooperative Ewing's sarcoma study (EICESS) the median age was 14 years. In the EICSS 24.7% of lesions presented in the pelvis, 16.4% in the femur, 16.7% below the knee, 12.1% in the ribs, 8.0% in the spine and 4.8% in the humerus.3
Ewing's family of tumour present both as osseous and extra osseous variants as well as in primitive neuroectodermal tumours (PNET'S) of bone and soft tissue, peripheral primitive neuroectodermal tumour, Askin tumour and some central nervous system tumours.2 Primary Ewing's sarcoma occurring in the kidney is a rare neoplastic disease of high malignant potential with a tendency towards early metastases. Approximately 20% of patients present with metastatic disease. Effective local as well as systemic therapies are necessary to cure this highly virulent disease.3 The presentation and prognosis of the disease in this case was almost similar to that of ES of bone.
We report a case of a 13-year-old girl who was diagnosed to have Ewing's sarcoma of kidney with lung and liver metastases.


Case Report

A 13 years young girl presented with right sided abdominal pain for one month and haematuria for 2 days. IVP was done which showed a non functioning right kidney. CT scan of abdomen and pelvis showed a large infiltrating mass measuring 6.0 x 9.0 cm occupying the central portion of the right kidney. The tumour was located entirely within the Gerota's fascia with no evidence of fascial breach at any level. There was evidence of peri renal lymphadenopathy. There was focus of non enhancing lesion in segment 4 of the liver measuring 1.0 x 1.5 cm. Multiple nodules were present in the lung bases bilaterally. Ultrasound guided Biopsy of right renal mass showed possibility of ES/PNET. She underwent right radical nephrectomy and the histopathology was consistent with a tumour with rounded blue cell and focally tumour was disrupting the renal capsule and extending into the peri renal fat. Hilum showed infiltration of tumour around the major blood vessels. The sections were submitted to a panel of immunohistochemical studies. PAS stain showed focal glycogen in tumour cells. Immunohistochemical studies showed strong positivity to Vimentin, MIC-2 and S-100 and focal positivity to EMA, Cytokeratin AE1/AE3 and Synaptophysin. Cytokeratin 7, LCA and Desmin were negative. On the basis of these findings diagnosis of Ewing's sarcoma/PNET of Kidney was made.


After confirmation of the diagnosis she received 6 cycles of CVD+IVE (3 cycles of cyclophosphamide, vincristine, doxorubicin and 3 cycles of vincristine, Etoposide and ifosphamide). This was followed by radiotherapy to tumour bed 50 Gy and later by 4 more cycles of chemotherapy with the same regime. The duration of chemotherapy was 11 months. CT scan of chest abdomen and pelvis done after 6 cycles of chemotherapy showed complete response in local as well as in distant areas and it was showing no evidence of disease at local site as well as in lungs. Repeat CT scan after completion of radiotherapy was also reported to show no evidence of disease. She was advised to have close follow up, unfortunately lung metastases reappeared 21 months after completion of therapy. At relapse of disease she was offered palliative radiotherapy to lungs for control of symptoms. There was slight improvement in her symptoms but expired 5 months after the discovery of recurrent lung mets.


Discussion

Ewing's sarcoma (ES) initially was believed to be of perivascular endothelial origin. The Ewing's sarcoma family of tumours (EFT) includes ES of bone (ESB), extra osseous ES (EES), peripheral primitive neuroectodermal tumour of bone (pPNET), and malignant small-cell tumour of the thoracopulmonary region, or Askin's tumour, all of which are now known to be neoplasm's of neuroectodermal origin. Because the behaviour, prognosis, and treatment appear to be similar for all subsets of EFT, this histopathologic sub classification may not be clinically significant.4
Light microscopy shows a tumour of small, round blue cells that lacks markers for lymphoma, neuroblastoma and rhabdomyosarcoma. Cytogenetically 90% to 95% of the Ewing's family of tumours have a translocation between the EWS gene on chromosome 22 and the FLI1 gene on chromosome 11 [t (11:22) (q24:q12)] or the ERG gene on chromosome 21 [t (21; 22) (q22; q12)].5
Approximately 20% of patients present with metastatic disease, of metastatic patients, 44% present with lung metastases only and 51% have bone or bone marrow involvement (with or without lung metastases) and 5% present with metastases in other organs.3 Effective local and systemic therapies are necessary for the cure of Ewing's sarcoma. Most chemotherapy regimens are a combination of cyclophosphamide, doxorubicin (Adriamycin), vincristine dactinomycin, ifosphamide and etoposide. Both surgery and radiation therapy are effective local therapy for the primary lesion.6-8
Ewing's sarcoma/primitive neuroectodermal tumour of kidney is a rare and aggressive tumour, only few cases are reported in the literature. It has a rapid clinical progression with early metastases and death.2 Jimenez et al published clinicopathologic and immunohistochemical analysis of 11 cases of Primary Ewing's sarcoma/PNET of the kidney and mentioned a mean age of 18-49 years and mean follow up of 28 months (range 6-64 months) which showed 4 lung and pleural metastases, 1 bone metastases, liver metastases, 2 local recurrences and 5 deaths from disease (median time to death 16.8 months).9 In the case we are presenting the overall survival was 26 months with distant relapse free survival was 21 months, and the history of our case is almost similar to this analysis and represent a typical ES/PNET of kidney affecting a young female patient.
Since 1991, bone and soft tissue Ewing's tumour have been treated similarly. The 5 year overall survival rate of patient is more than 40% with localized disease at diagnosis. The prognosis of patients with metastatic disease at diagnosis is poor. In a report from the EICSS, the 5-year relapse free survival for patients with lung metastases only was 29%. In patients with metastatic disease at diagnosis, less than 50% of all Ewing's sarcoma patients survive and it has been difficult to show a significant improvement over the last 20 years. Presently dose intensification by decreasing the interval between cycles is being studied, using VACA/ifosphamide-etoposide chemotherapy. With regards to local therapy the focus should be on improving function and decreasing the incidence of long term sequelae. It is unlikely that refinements in local therapy with radiotherapy or surgery will significantly improve the cure rate. Metastases remain the primary mechanism of failure, and major improvements in the long term survival rates will probably not occur until the development of better systemic agents or genetic therapy targeted at the unique translocation that produce these malignancies.10,11


References

1.Parada D, Godoy A, Liuzzi F, Pelia KB, Romero A, Parada AM.Primary Ewing's sarcoma/primitive neuroectodermal tumour of the kidney. An infrequent finding. Arch Esp Urol 2007; 60: 321-5.
2.Saxena R, Sait S, Mhawech-Fauceglia P. Ewing sarcoma/primitive neuroectodermal tumour of the kidney: a case report. Diagnosed by immunohistochemistry and molecular analysis. Ann Diagn Pathol 2006; 10: 363-6.
3.Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, et al. Prognostic factors in Ewing's tumour of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's  Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-14.
4.Carvajal R, Meyers P. Ewing's sarcoma and primitive neuroectodermal family of tumours. Hematol Oncol Clin North Am 2005; 19: 501-25.
5.Sandberg AA, Bridge JA. Updates on cytogenetics and molecular genetics of bone and soft tissue tumours: Ewing's sarcoma and peripheral primitive neuroectodermal tumours. Cancer Gen Cytogenet 2000; 123: 1-26.
6.Arai Y, Kun LE, Brooks MT, Fairclough DL, Fontanesi J, Meyer WH, et al. Ewing's sarcoma: local tumour control and patterns of failure following limited -volume radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21: 1501-8.
7.Bacci G, Picci P, Mercuri M, Ferrari S, Longhi A, Cesari M, et al. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. Acta Oncol 1998; 37: 671-6.
8.Cangir A, Vietti JJ, Gehan EA, Burgest EOJr, Thomas P, Tefft M, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparison of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887-93.
9.Jimenez RE, Folpe AL, Lapham RL, Ro JY, O'Shea PA, Weiss SW, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumour of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases. Am J Surg Pathol 2002; 26: 320-7.
10.Robert B, Marcus, Jr. Ewing's sarcoma. In: Principles and Practice of Radiation Oncology, 4th ed. Philadelphia. Lipincot Williams and Wilkins, 2002; pp 2277-82.
11.Price P, Sikora K. Bone, Ewing's family of tumours. In: Treatment of Cancer 4th ed. UK: Hodder Arnold publication, 2002; pp 863-5.


News & Events

Dear Friends and Colleagues,
May you have a very Happy EID with your friends and Family.
May all of us be Blessed with peace and tranquility.
Let us all jointly say a prayer for all troubled persons all over the world
Warm regards,
Dr. Fatema Jawad
Editor-in-chief,
Journal of Pakistan Medical Association, Karachi
President, PAME
Pakistan Association of Medical Editors



WHO/GOARN Request for technical assistance for Cholera Control in Northern Iraq

Request for assistance

WHO is requesting assistance from GOARN partners to identify the following cholera and diarrhoeal diseases expertise to support the Ministry of Health of Iraq in cholera risk assessment and immediate preparedness activities to improve the health outcomes of the Syrian refugees current living in camps in the Kurdistan region of Iraq.

  • two (2) epidemiologists
  • two (2) clinical management experts
  • one (1) environmental health expert (WATSAN)
  • one (1)laboratory expert

Duration

6 day mission starting 13 June 2014 (this excludes travel time).

Location

Northern Iraq (Kurdistan region).

Language requirements

All candidates must be fluent in English- written, spoken and comprehension. Fluency in Arabic is an asset. Knowledge, abilities and skills All candidates are expected to demonstrate the following

  • Ability to conceptualize and promote innovative strategies and policies.
  • Ability to communicate and write in a clear concise manner, and to develop effective guidelines.
  • Excellent negotiation and interpersonal skills complemented by ability to motivate and lead others and to promote consensus. Tact, discretion and diplomacy
  • Demonstrated ability for project appraisal, project management, monitoring and evaluation and project impact assessment.
  • Ability to work with host governments and their agents, INGOs and national NGOs an advantage.
  • Proven experience of managing a large workload and multiple priorities.
  • Ability to work in difficult conditions.

Support to the mission

WHO/GOARN will cover the travel and per diem (to cover daily expense in the field) expenses for the duration of their mission. GOARN missions do NOT offer salary, consultancy fees or any other form of remuneration.

WHO will provide appropriate logistics support for the field mission. Pre-deployment orientation/training may be required at WHO.

Partners offers of assistance

Partners are requested to reply with offers of assistance, together with CVs and details of the availability of staff for this mission by email to goarn@who.int latest by 30 May 2014. Details of all offers from partners and eventual deployments will be maintained on the GOARN SharePoint.

Operational Contacts

Mamunur Malik WHO EMRO malikm@who.int

William Perea WHO HQ pereaw@who.int

Patrick Drury GOARN druryp@who.int



News



Index



Supplement